NKTR
Nektar Therapeutics Hits a High Note in Q2 2026: REZPEG Advances to Phase III, Market Opportunity Shines
Nektar Therapeutics, a biopharmaceutical company focused on developing innovative therapies for patients with serious and complex diseases, has announced another significant milestone in its Q2 2026 financial results. The company's President and Chief Executive Officer, Howard Robin, highlighted the initiation of the global ZENITH AD program, a Phase